Home2020-01-23T19:50:26+00:00
Loading...
Loading...

Spotlight

Twitter feed

A group of distinguished oncology leaders from countries in the Asia Pacific region are advising on the needs of our members & facilitating member involvement in global activities. https://t.co/YwWLmDlNJE #ASCOconnection #ASCOInternational

“The payoffs of cancer prevention are huge."
ICYMI: #AACRFellows and Past President @Rndubois shared his predictions for the field of cancer prevention in 2021.
Learn more on the #AACRBlog:
https://t.co/e84l1fjwDV

.@US_FDA today approved Melflufen for the treatment of adult patients with triple-class refractory multiple #myeloma

Dana-Farber’s Paul Richardson, MD, comments on what this approval means for patients 👇

.@rschilsky Bids Adieu to ASCO — As chief medical officer, he made oncologist group into an important research engine. By @icingram via @medpagetoday 

Richard Schilsky Bids Adieu to ASCO

As chief medical officer, he made oncologist group into an important research engine

fal.cn

February is National Cancer Prevention Month. AACR Active members receive free access to one AACR journal and reduced subscription rates to all other journals— including our two prevention journals, @CEBP_AACR and @CAPR_AACR. Learn more:
https://t.co/vEcbcfSYMz

Genomic architecture and targets in hypoxic tumors:
Robert G. Bristow @OfficialUoM will address this topic in a keynote address at the AACR virtual conference on Radiation Science and Medicine, March 2-3. Learn more:
https://t.co/a9YnG3silN
#AACRrsm21

Sirtuins, Cell Homeostasis, and Metabolism:
David Gius @UTHealthSA, @carmenbergom @WUSTL, Fen Xia @UAMS, and Douglas R. Spitz @uiowa will discuss this topic at the AACR virtual conference on Radiation Science and Medicine, March 2-3:
https://t.co/3PUsxXSf7Z
#AACRrsm21

Thanks to the generous support of a new funding partner, @ConquerCancerFd developed a program aimed at recruiting and retaining young physician-scientists committed to research in symptom management #ASCOconnection

Conquer Cancer, Rising Tide Foundation for Clinical Cancer Research

Conquer Cancer, the ASCO Foundation, has a new funding partner for a program aimed at recruiting and retaining young physician-scientists committed to...

fal.cn

Recent publications

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy.

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell.

All publications

Announcements

We’re pleased to share a new section on our site, “Our stories,” which will profile staff from the Belfer team. Our first story is Sarah Musoke (Nzikoba). Read Sarah’s story.

Research

Target identification and validation image
Target identification and validation
Photo of scientist carefully adding fluid to multiple test tubes
Drug discovery and development
Photo of Belfer Center researcher working at computer
Clinical science and correlatives

Strategic alliances

Graphic showing circular relationship of research, medicine, and industry

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients

Collaborate with us

Our people

Background image is a collage of photos showing Belfer Center members
Our team
Our culture
Background image is a collage of photos showing Belfer Center members

Donor highlight

Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.

Photo of donors, Mr. and Mrs Belfer
Go to Top